Related Experiment Video
Updated: May 14, 2026
12:40
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance
Alfonso Quintás-Cardama1, Srdan Verstovsek
1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Summary
Aberrant JAK/STAT pathway activation drives diseases like myeloproliferative neoplasms (MPNs). JAK inhibitors show promise, but resistance mechanisms are emerging, necessitating new therapeutic strategies.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- The Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway is aberrantly activated in various diseases, including hematologic malignancies and solid tumors.
- Gain-of-function JAK2 V617F mutation is prevalent in myeloproliferative neoplasms (MPNs), highlighting the pathway's pathogenic role.
- JAK inhibitors, such as ruxolitinib, have been developed to suppress this aberrant activation and show clinical activity in MPNs.
Purpose of the Study:
- To review the role of JAK/STAT pathway activation in disease pathogenesis.
- To discuss the development and clinical application of JAK inhibitors for MPNs and other cancers.
- To explore emerging mechanisms of resistance to JAK inhibitor therapy and potential strategies to overcome it.
Main Methods:
- Literature review of studies on JAK/STAT pathway activation, JAK inhibitors, and resistance mechanisms.
- Analysis of clinical trial data for JAK inhibitors in MPNs, lymphoma, and solid tumors.
- Synthesis of recent findings on molecular mechanisms underlying resistance to JAK kinase inhibitors.
Main Results:
- JAK/STAT pathway dysregulation is a common feature in various malignancies.
- JAK inhibitors have demonstrated significant clinical efficacy in myelofibrosis and other hematologic conditions.
- Mechanisms of resistance to JAK inhibitors have been identified, impacting treatment outcomes in some patients.
Conclusions:
- Targeting the JAK/STAT pathway with inhibitors represents a significant therapeutic advance for MPNs and other cancers.
- Understanding and overcoming resistance mechanisms are critical for improving patient response to JAK inhibitor therapy.
- Further research into novel therapeutic strategies is warranted to address treatment resistance and enhance clinical outcomes.
More Related Videos
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:19Interactions Between Signaling Pathways
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
01:07MAPK Signaling Cascades
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:22Amplifying Signals via Enzymatic Cascade
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...